The Founder of Coinbase Is Going to Research Immortality

marsbitPublicado em 2026-06-03Última atualização em 2026-06-03

Resumo

Coinbase founder Brian Armstrong has co-founded NewLimit, a longevity biotech startup, which just raised $435 million in a Series C funding round led by Peter Thiel’s Founders Fund. The round values the company at $3.1 billion, more than triple its valuation from a year ago. NewLimit is developing drugs aimed at reversing cellular aging to extend human healthspan. Its approach builds on Nobel Prize-winning research on cellular reprogramming (Yamanaka factors), with a focus on identifying specific gene combinations that can restore younger cell function. The company plans to begin human clinical trials next year, initially targeting alcohol-related liver disease as a form of accelerated aging. Founded in 2021 by Armstrong alongside biotech investor Blake Byers and scientist Jacob Kimmel, NewLimit has now raised over $700 million across multiple rounds. It joins a growing field of well-funded longevity ventures backed by tech billionaires, including Sam Altman’s Retro Biosciences and Jeff Bezos-backed Altos Labs, reflecting a surge of interest in using science to combat aging and extend healthy lifespan.

Author | Azuma(@azuma_eth)

At 3:00 AM Beijing time on June 3, longevity technology startup NewLimit announced the completion of a $435 million Series C funding round. This round was led by Peter Thiel's fund Founders Fund, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, Valor Equity Partners, among others, while also introducing new investors such as Thrive Capital, Greenoaks, and Quiet Capital.

A WSJ report indicated that NewLimit's valuation in this round reached $3.1 billion, more than triple its valuation from a year ago.

In its funding announcement, NewLimit revealed that following breakthrough research achievements, the company is advancing longevity medicine into the human clinical trial stage. Its first drug targeting alcohol-related liver disease is expected to commence clinical trials next year.

NewLimit also emphasized: "By reprogramming cell age, humans may achieve longer health spans, and now, we are closer than ever to the goal of delaying or even reversing aging."

The Founder Turns Out to Be an Old Acquaintance

It is worth mentioning that one of NewLimit's co-founders is none other than our old acquaintance — Coinbase founder and CEO Brian Armstrong.

In 2021, Brian Armstrong, together with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, invested $110 million to establish NewLimit in South San Francisco.

Picture: The NewLimit founding team

Prior to this funding round, NewLimit had already completed three rounds of financing, as detailed below.

May 2023: Completed a $40 million Series A round, with investors including Dimension, Founders Fund, and Kleiner Perkins;
May 2025: Completed a $130 million Series B round, reaching a valuation of $810 million, led by Kleiner Perkins, with participation from Founders Fund, Khosla Ventures, and Human Capital, among others;
October 2025: Received an additional $45 million investment, bringing the post-money valuation to $1.62 billion, with investors including Lilly Ventures, Duke University, Section 32, etc.;

According to NewLimit's official introduction, the company is dedicated to developing drugs that can extend human health span — "As humans age, cellular function gradually declines, making people more susceptible to diseases. It was once believed that aging was inevitable, but emerging science shows that the aging process can be reversed at the cellular level. We are developing the first drugs based on these discoveries to restore the youthful function of aging cells."

In simpler terms, NewLimit is using scientific methods to research immortality!

Reversing Aging is Not a Fantasy

Over the past few decades, while the scientific community has long recognized the link between aging and cellular functional decline, it could not precisely find a way to make cells "rejuvenate." The turning point came in 2006 when Japanese scientist Shinya Yamanaka discovered that activating just a few specific transcription factors could reprogram adult cells into a youthful state resembling embryonic stem cells. This discovery was later named "Yamanaka Factors" and helped him win the 2012 Nobel Prize in Physiology or Medicine.

Odaily Note: Picture shows Shinya Yamanaka speaking in Tokyo

Yamanaka's research first proved something previously considered impossible — that cellular age is not irreversible. And the story told by NewLimit is built precisely upon this discovery.

NewLimit writes on its website: "Our drugs can reprogram a cell's epigenome to a younger state by activating specific transcription factor genes. We already know this reversal is possible. However, for different cell types, exactly which combinations of transcription factors are needed to restore their youthful function remains unknown. Finding and discovering these effective payloads is the core challenge of our work."

NewLimit's strategy is to first target a specific disease to obtain drug approval, and then explore broader applications. As mentioned earlier, NewLimit is advancing a drug for alcohol-related liver disease into clinical trials.

NewLimit Co-founder and CEO Jacob Kimmel further explained, "Liver disease can actually be viewed as an 'accelerated version of aging,' it just presents the aging process that everyone experiences in a faster and more intense manner."

The Biggest Investors in This Sector Are All Billionaires

NewLimit is not the only tech company currently targeting "immortality."

In 2022, Sam Altman invested $180 million in Retro Biosciences, which is developing drugs to rejuvenate aging cells. Last month, Retro Biosciences disclosed its valuation had reached $1.8 billion.

Furthermore, Altos Labs, reportedly backed by Jeff Bezos's funding, also launched in 2022 with $3 billion and has since raised nearly twice that amount in total funding.

It's easy to see that from Peter Thiel to Sam Altman to Jeff Bezos, the biggest investors in this sector are without exception super-rich individuals at the pinnacle of technology and wealth. Peter Thiel has publicly expressed extreme aversion to death, advocating similar views on multiple occasions: "Death is humanity's greatest enemy, yet we treat it as a natural law..."

The logic behind these tech titans' willingness to invest hundreds of millions is not hard to understand — when wealth and power reach their peak, time becomes the only enemy, the only luxury that cannot be bought directly with money.

Having earned enough money, "how to live longer" becomes the greatest challenge.

Perguntas relacionadas

QWhat is NewLimit, and what is its primary goal?

ANewLimit is a longevity biotechnology startup. Its primary goal is to develop drugs to extend human healthspan by reversing the aging process at the cellular level.

QWho is the notable co-founder of NewLimit mentioned in the article?

AThe notable co-founder is Brian Armstrong, who is also the founder and CEO of the cryptocurrency exchange Coinbase.

QWhat scientific breakthrough is NewLimit's research based on?

ANewLimit's research is based on the discovery of the 'Yamanaka Factors' by Japanese scientist Shinya Yamanaka in 2006, which showed that adult cells can be reprogrammed into a younger, pluripotent state.

QHow much funding did NewLimit recently raise and at what valuation?

ANewLimit recently raised $435 million in a Series C funding round, which valued the company at $3.1 billion.

QWhy are super-wealthy tech figures like Peter Thiel and Sam Altman investing in longevity companies?

AFor super-wealthy individuals, time is seen as the ultimate luxury that money cannot directly buy. After achieving immense wealth and power, extending their healthspan and potentially reversing aging becomes a primary focus.

Leituras Relacionadas

Will the Next Crypto Bull Run Start with On-Chain Trading of SpaceX?

This article presents a scenario-based forecast for the crypto industry from 2026 to 2029, arguing that the next major cycle will be driven not by technological narratives but by legal access to real-world assets. The author predicts that by mid-2026, pre-IPO perpetual contracts for top private companies like SpaceX, OpenAI, and Anthropic on platforms like Hyperliquid will become the primary gateway for accessing quality assets, as most crypto-native tokens fail to capture real value. The much-hyped AI x Crypto intersection largely fails except for prediction markets, which thrive on betting on AI model supremacy. By 2027, public blockchain foundations are forced to choose between catering to retail speculation or building compliant infrastructure for institutions, with many opting for the latter. Growth in stablecoins and tokenized private credit/equity hits a "triple ceiling" due to regulatory and political uncertainty rather than market demand. The pivotal shift is forecast for 2028. A major liquidation event in pre-IPO perpetuals exposes the structural flaw of synthetic markets lacking a real underlying asset anchor. In response, regulatory changes finally allow the public solicitation of private securities resales to verified accredited investors. This creates a legitimate secondary market for real company equity, which then becomes the core asset class of the new bull market, relegating synthetic perps to a niche role. By 2029, the industry becomes "boring" but foundational. Tokens without claims on real cash flows or assets cease trading. Stablecoin growth is steady but politically capped. Crypto infrastructure fades from view as it gets absorbed into traditional finance backends. The article's central thesis is that the key bottleneck for crypto's next phase is legal and regulatory channels for real asset ownership, not technology.

marsbitHá 10m

Will the Next Crypto Bull Run Start with On-Chain Trading of SpaceX?

marsbitHá 10m

Kalshi-CFTC Fight In New Mexico Could Shape Prediction Market Rules

A jurisdictional battle between the U.S. Commodity Futures Trading Commission (CFTC) and the state of New Mexico over the regulation of prediction markets could set national rules for the industry. At issue is who polices platforms like Kalshi, with the CFTC asserting federal oversight and New Mexico arguing state gaming and consumer protection laws apply, especially for contracts resembling wagers on events like elections or sports. The outcome will determine if prediction markets can scale nationally under a clear federal framework or face a fragmented, state-by-state regulatory landscape. This dispute is significant for the crypto-adjacent trading community, which often engages with these speculative event markets. A clearer rulebook could boost mainstream adoption, liquidity, and integration with crypto infrastructure, while a state-led challenge could stifle growth. The case is particularly sensitive for sports-related contracts, where the line between financial markets and gambling blurs. Ultimately, this legal fight will shape whether prediction markets become a scalable national product or remain constrained by jurisdictional conflicts.

bitcoinistHá 1h

Kalshi-CFTC Fight In New Mexico Could Shape Prediction Market Rules

bitcoinistHá 1h

The Value Distribution of Stablecoins

**Summary: The Value Distribution of Stablecoins** The article argues that stablecoins are evolving from mere trading tools into broader channels for dollar access. It divides the stablecoin ecosystem into four layers to analyze how value is distributed: 1. **Issuance Layer:** Mints stablecoins, holds reserve assets, and captures the spread between reserve yield and user costs (e.g., Tether, Circle). This layer currently earns the largest profit margin. 2. **Infrastructure Layer:** Connects stablecoins to the traditional financial system, handling fiat on/off-ramps, banking integration, compliance (KYC/AML), and asset management (e.g., Bridge, BVNK). This is the "unglamorous" but critical work, building the essential bridges between crypto and real-world finance. 3. **Acquiring/Distribution Layer:** Integrates stablecoins into merchant systems, manages payment flows, and provides enterprise financial software (e.g., Stripe, Coinbase). They act as the access point for businesses. 4. **Application Layer:** The end-users and businesses that ultimately use stablecoins for payments, settlements, or as a store of value. They benefit from convenience but have little pricing power. The core thesis is that while the issuance layer currently dominates profits, the often-overlooked **infrastructure layer holds significant long-term potential**. The real challenge and barrier to mass adoption is not the on-chain transfer of stablecoins (which is simple), but the complex "last mile" integration into existing business workflows, banking systems, and regulatory frameworks across different countries. Companies in this layer are currently in a "land grab" phase, investing heavily to build networks, secure bank partnerships, and establish compliance pathways. While their position is currently pressured by the profitable issuers above and distribution platforms below, the article suggests that if stablecoins become a default financial rail for businesses, the infrastructure providers who have done the hard work of integration will ultimately gain strong pricing power and become entrenched, essential players.

marsbitHá 6h

The Value Distribution of Stablecoins

The Value Distribution of Stablecoins The article argues that stablecoins are evolving from a mere trading tool into a broad "dollar channel." It analyzes the industry's value chain through four layers: 1. **Issuance Layer (e.g., Tether, Circle):** The top layer that mints stablecoins, holds reserve assets, and captures the thickest interest rate spread. 2. **Infrastructure Layer (e.g., Bridge, BVNK):** Connects stablecoins to the traditional financial system, handling critical but complex "dirty work" like fiat on/off-ramps, banking integration, compliance (KYC/AML), and cross-border settlement. 3. **Acquiring/Distribution Layer (e.g., Stripe, Coinbase):** Embeds stablecoins into merchant systems, manages payment flows, and integrates with enterprise software. 4. **Application Layer:** End-users and businesses that ultimately use stablecoins for payments, settlement, or storing value. The author posits that while the issuance layer currently captures the most profit, the most overlooked and potentially critical layer is infrastructure. The core challenge for stablecoin adoption isn't the on-chain transfer (which is simple), but bridging the gap between blockchain and the real-world financial system. This involves solving practical problems for businesses: fiat conversion, reconciliation, tax handling, and user onboarding. Infrastructure companies are currently in a difficult "land-grab" phase—building networks, securing banking relationships, and achieving compliance country-by-country. They face pressure from both the profitable issuance layer above and distribution platforms below. However, the author suggests this layer is building a crucial moat. Once stablecoins become a default business rail, the infrastructure players who have done the hard work of integration may gain significant, durable value and pricing power.

链捕手Há 6h

Why Is Nvidia Borrowing $20 Billion When It's Not Short of Cash?

Nvidia's recent announcement to issue at least $20 billion in senior notes, despite holding a strong cash position with over $48.6 billion in free cash flow last quarter, is not a sign of financial need. Instead, it represents a strategic move to leverage its high credit rating (recently upgraded to AA by S&P) to secure low-cost, long-term debt. This capital will support long-term AI infrastructure investments, data centers, R&D, supply chain prepayments, and strategic investments, while allowing the company to continue aggressive shareholder returns through stock buybacks and dividends. The decision reflects a mature capital management strategy: using debt to finance long-term growth assets is more efficient and less dilutive to shareholders than equity financing. It signals that Nvidia, like other tech giants (Alphabet, Meta, Amazon), is entering a new phase of heavy AI capital expenditure, shifting from a pure growth story to a story about capital allocation, credit strength, and long-term ecosystem positioning. The key question for investors is whether Nvidia can maintain its high cash flow generation and ensure that returns from these AI investments justify the cost of capital over the long term. The bond issuance amplifies its expansion capabilities but also ties its valuation more closely to the broader AI investment cycle's sustainability and profitability.

marsbitHá 7h